Publications by authors named "N L Geller"
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Cross-Trial Statistics Group gathered lessons learned from statisticians responsible for the design and analysis of the 11 ACTIV therapeutic master protocols to inform contemporary trial design as well as preparation for a future pandemic. The ACTIV master protocols were designed to rapidly assess what treatments might save lives, keep people out of the hospital, and help them feel better faster. Study teams initially worked without knowledge of the natural history of disease and thus without key information for design decisions.
View Article and Find Full Text PDFDisease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2-years after biologic assignment to a Donor or No Donor (SOC) Arm based on the availability of an HLA-matched sibling or unrelated donor (BMTCTN 1503; NCT02766465). A donor search was commenced after eligibility confirmation.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to see if treating mild chronic hypertension (CHTN) during pregnancy would lead to fewer unplanned healthcare visits after childbirth.
- - An analysis of 2,293 pregnant patients showed that overall unplanned healthcare utilization rates were similar between the treatment and control groups, though emergency visits were notably lower in the treated group.
- - Factors like higher BMI and cesarean deliveries were found to increase the likelihood of needing unplanned postpartum care, even though treating mild CHTN showed some specific benefits.
Article Synopsis
- CYP2C19 loss of function carriers face a higher risk of ischemic events when treated with clopidogrel during PCI.
- In the TAILOR-PCI study, patients were randomized to receive either clopidogrel or a genotype-guided therapy where LOF carriers were prescribed ticagrelor.
- Although direct medical costs were similar between the two groups, total costs were higher for the GG group mainly due to the more expensive ticagrelor medication.